• Mashup Score: 21
    Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C - 2 day(s) ago

    Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) from birth, leading to accelerated atherosclerotic cardiovascular disease and premature death if untreated. Evinacumab, a monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3), offers an LDL receptor-independent pathway to lower LDL-C. This study aimed to evaluate the effect of evinacumab on lipid levels and its potential to reduce lipoprotein apheresis (LA) frequency in children and adolescents with HoFH.

    Source: www.atherosclerosis-journal.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of SABOURETCardio
      SABOURETCardio

      #Evinacumab and reduced lipoprotein apheresis in pediatric #HoFJ : a retrospective study on LDL-C - #Atherosclerosis https://t.co/mZDyDkqqOL

  • Mashup Score: 20
    Air pollution and atherosclerosis - 3 day(s) ago

    Air pollution is associated with considerable cardiovascular mortality and morbidity. The vascular disease atherosclerosis underlies many cardiovascular conditions, with atherosclerotic plaque rupture being a trigger for stroke and myocardial infarction. The acute and chronic effects of air pollution have the potential to exacerbate many different facets of atherosclerosis. This review provides an overview of how air pollution promotes the development of atherosclerosis. The review summaries the epidemiological evidence between exposure to air pollution and morphological measures of atherosclerosis such as carotid intimal media thickness, coronary artery calcification and aortic artery calcification, before summarising the biological mechanisms by which air pollution promotes atherosclerosis at the different stages of disease progression.

    Source: www.atherosclerosis-journal.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of gonzaeperez
      gonzaeperez

      POLUCIÓN AMBIENTAL Y ATEROSCLEROSIS Un problema 🌎 que impacta en la formación y exacerbación de la aterosclerosis Compuestos volátiles➡️🫁➡️inflamación, vasos sanguíneos y alteraciones endócrinas➡️ Daño vascular, cardíaco y sanguíeneo @ATHjournal https://t.co/lXHsCkKUuf https://t.co/g6m2u2okfS

  • Mashup Score: 11
    Metabolic, renal, and inflammatory crosstalk in atherosclerotic cardiovascular disease: Evolving landscape and future directions - 10 day(s) ago

    Renal and metabolic dysfunction are major contributors to atherosclerotic cardiovascular disease (ASCVD) [1,2]. Although underlying risk factors including chronic kidney disease (CKD), diabetes mellitus (DM), excess visceral adiposity, and dyslipidemia are each independently associated with ASCVD, important mechanistic and clinical synergies exist between these conditions. For instance, in diabetic kidney disease, metabolic stress and related damage-associated molecular patterns trigger inflammatory responses in the kidney and vasculature, leading to tissue damage and related progression of CKD and ASCVD (Graphical Abstract) [3].

    Source: www.atherosclerosis-journal.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of SABOURETCardio
      SABOURETCardio

      Metabolic, renal, and inflammatory crosstalk in #ASCVD : Evolving landscape and future directions - #Atherosclerosis https://t.co/ptSiDuRIsc

  • Mashup Score: 2
    The Brussels International Declaration on Lipoprotein(a) Testing and Management - 1 month(s) ago

    There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1%-2%) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations.The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24-25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization.

    Source: www.atherosclerosis-journal.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of mitcharj
      mitcharj

      The Brussels International Declaration on Lipoprotein(a) Testing and Management https://t.co/lJPkpWSPfN

  • Mashup Score: 6
    Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening - 2 month(s) ago

    An elevated level of lipoprotein(a), or Lp(a), in the bloodstream has been causally linked to the development of atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Steady state levels of circulating lipoproteins are modulated by their rate of clearance, but the identity of the Lp(a) uptake receptor(s) has been controversial.

    Source: www.atherosclerosis-journal.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of DrScottMurray
      DrScottMurray

      Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening - Atherosclerosis https://t.co/MkM8WRv3H4 Let's go deeper into Inception...@lipo_fan @ApoDudz @JoshJwageman @Clint_OMeley @Lpa_Doc @JohnKastelein @Drlipid

Load More